IMMUNE · Injectable
GcMAF.
Macrophage activating factor — innate immune modulation
How it works
Class & mechanism.
In short
GcMAF (Gc protein-derived Macrophage Activating Factor) is a glycoprotein theorized to activate macrophages, the immune cells that identify and clear abnormal or infected cells. Most of the foundational research behind it was retracted for ethical irregularities, and its best-known commercial manufacturer was criminally prosecuted for unlicensed production. A small FDA-registered Phase 1 trial has since evaluated its safety in advanced cancer patients, but this establishes tolerability only — not efficacy, and not treatment of any disease.
Class
Glycoprotein / Immune Modulator
Mechanism
GcMAF (Gc Protein-Derived Macrophage Activating Factor) is produced by sequential deglycosylation of the vitamin D-binding protein (Gc protein). The deglycosylation is naturally mediated by lymphocyte-derived enzymes (B and T cells). The resulting ~51 kDa glycoprotein is proposed to activate macrophages, which is theorized to make them cytotoxic to tumours and pathogens. Critical note: three of four original GcMAF studies by Yamamoto were retracted in 2014 due to ethical irregularities. The Sheba Hospital (Israel) completed a Phase 1 FDA-registered trial (NCT02052492) on EF-022 as of May 2017 — this is the most rigorous dataset available.
Personalized Peptides provides DNA-driven peptide recommendations — we are not a compounding pharmacy, peptide synthesis company, or clinical provider.
Did you know
GcMAF is one of the most controversial molecules in immunology — its original research was retracted, its most prominent manufacturer was imprisoned, yet a legitimate Phase 1 clinical trial at a major Israeli hospital confirmed it's safe enough to study. The truth is somewhere in the middle.
Preclinical Data
No human PK studies available.
⚠ Contested research — foundational papers retracted. No reliable PK data.
Class
Vitamin D-binding protein-derived macrophage activating factor
Route
SC / IM
Mol. Weight
52,000 Da
What we don't know
The entire GcMAF evidence base is compromised. Multiple foundational papers from the Yamamoto group have been retracted. No reliable PK data exists. The large molecular weight (~52 kDa) suggests very poor SC bioavailability, rapid proteolytic degradation, and negligible oral absorption. Any commercial GcMAF product faces fundamental questions about whether the claimed active molecule can reach target tissues intact.
Why this dosing protocol
Reported protocols (100ng-1mcg SC weekly) are completely unvalidated. The nanogram dosing level is orders of magnitude below what would be expected to produce systemic effects from a 52 kDa protein with essentially zero oral bioavailability. This product should be approached with extreme caution.
Empirical protocol: 100ng-1mcg SC weekly
Safety notes
- Retracted foundational research
- No reliable PK data
- 52 kDa protein — negligible SC BA likely
Pharmacokinetic data shown for educational context. All parameters are inferred or empirically derived — no formal human PK studies exist for this compound. Individual response varies. Not a substitute for clinical dosing guidance.
Benefits
What it does.
Macrophage activation — proposed to stimulate innate immune response through enhanced macrophage cytotoxicity
Immune surveillance — theoretical enhancement of the body's ability to identify and eliminate abnormal cells
Chronic infection support — investigated for immune modulation in persistent viral and bacterial conditions
The science
Peer-reviewed findings.
Research supporting this compound's mechanisms and safety profile.
What this does not mean
GcMAF is a research chemical with a compromised evidence base — most of its original supporting studies were retracted for ethical irregularities, and unlicensed manufacture has resulted in criminal prosecution. The information on this page is educational and does not constitute medical advice, diagnosis, or treatment. GcMAF is not FDA-approved for the treatment of any disease, including cancer, and has no FDA-approved indications of any kind. This page does not recommend, endorse, or prescribe any compound for human use. Always consult a qualified healthcare provider before making health decisions. Personalized Peptides provides DNA-driven educational context and test interpretation — not clinical protocols or pharmaceutical recommendations.
Phase 1 FDA-registered clinical trial (NCT02052492) at Sheba Hospital, Israel completed May 2017 — EF-022 (GcMAF) safety and tolerability established in advanced solid malignancies; primary endpoint met
SOURCE · NCT02052492 — Phase 1 open-label dose-escalation, Sheba Hospital; presented at AACR-NCI-EORTC 2015, Abstract B30
Protocol
How to use it.
Dosing
100–500 ng intramuscular injection, once or twice weekly. Historical Yamamoto protocols (now discredited) used 100 ng IM weekly × 16–22 weeks.
Cycle
Not formally established. Underground protocols range from weekly dosing for 16–22 weeks to biweekly maintenance. Clinical guidance essential.
Contraindications
When to skip it.
Core research largely retracted/fraudulent (Yamamoto, 2014). Manufacturing without license is criminal offence in UK (David Noakes case). Commercial product purity and composition are not guaranteed. Cancer Research UK and the Anticancer Fund have issued strong public warnings. NOT approved in any jurisdiction for any indication.
Always cleared with your concierge before protocol start.
Regulatory Context
FDA compounding status.
| FDA Status | Risk Level | Compounding | Key Date |
|---|---|---|---|
| No FDA approval — enforcement history exists | 🟡 Under Review | Not FDA-approved — historical enforcement actions | No pending dates |
Gc Macrophage Activating Factor. Not FDA-approved. Historical FDA enforcement actions against GcMAF marketing claims (cancer treatment). Any PP content must strictly avoid disease-treatment claims. Research-use-only framing.
Source: FDA Federal Register, PCAC agendas, industry analyses. Educational context only — not legal advice. Review after July 23-24, 2026 PCAC meeting.
Pricing
What it costs.
Indicative range for GcMAF, sourced from vetted US and EU dispensing suppliers. Concierge confirms the exact figure once your match is locked.
Indicative range (USD)
Sourced through vetted dispensing partners in the United States and European Union. Concierge confirms the exact figure once your match is locked.
- 0199% purity verified, third-party tested
- 02Includes vial and reconstitution guidance
- 03Concierge supplier match included with every protocol
See GcMAF pricing — and your supplier match.
Pricing is unlocked once we know who you are. Take the 3-minute quiz and we'll match you to a US or EU dispensary based on your location and protocol fit.
- Live USD price range
- US & EU supplier shortlist
- Concierge sign-off on dosing
Indicative price range: $168–$252 USD